Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer

  • Kelvin K. Yap
  • Kenneth S. K. Yap
  • Amanda J. Byrne
  • Salvatore U. Berlangieri
  • Aurora Poon
  • Paul Mitchell
  • Simon R. Knight
  • Peter C. Clarke
  • Anthony Harris
  • Andrew Tauro
  • Christopher C. Rowe
  • Andrew M. Scott
Original Article

Abstract

Purpose

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging is an important staging procedure in patients with non-small cell lung cancer (NSCLC). We aimed to demonstrate, through a decision tree model and the incorporation of real costs of each component, that routine FDG-PET imaging as a prelude to curative surgery will reduce requirements for routine mediastinoscopy and overall hospital costs.

Methods

A decision tree model comparing routine whole-body FDG-PET imaging to routine staging mediastinoscopy was used, with baseline variables of sensitivity, specificity and prevalence of non-operable and metastatic disease obtained from institutional data and a literature review. Costings for hospital admissions for mediastinoscopy and thoracotomy of actual patients with NSCLC were determined. The overall and average cost of managing patients was then calculated over a range of FDG-PET costs to derive projected cost savings to the community.

Results

The prevalence of histologically proven mediastinal involvement in patients with NSCLC presenting for surgical assessment at our institution is 20%, and the prevalence of distant metastatic disease is 6%. Based on literature review, the pooled sensitivity and specificity of FDG-PET for detection of mediastinal spread are 84% and 89% respectively, and for mediastinoscopy, 81% and 100%. The average cost of mediastinoscopy for NSCLC in our institution is AUD$4,160, while that of thoracotomy is AUD$15,642. The cost of an FDG-PET scan is estimated to be AUD$1,500. Using these figures and the decision tree model, the average cost saving is AUD$2,128 per patient.

Conclusion

Routine FDG-PET scanning with selective mediastinoscopy will save AUD$2,128 per patient and will potentially reduce inappropriate surgery. These cost savings remain robust over a wide range of disease prevalence and FDG-PET costs.

Keywords

18F-fluorodeoxyglucose Cost effectiveness NSCLC Positron emission tomography Mediastinoscopy 

References

  1. 1.
    Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254–61.PubMedGoogle Scholar
  2. 2.
    Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999;16:1–6.Google Scholar
  3. 3.
    Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer; a prospective study. J Clin Oncol 2001;19:111–8.PubMedGoogle Scholar
  4. 4.
    van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–92.PubMedGoogle Scholar
  5. 5.
    Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113–25.PubMedGoogle Scholar
  6. 6.
    Keith CJ, Miles KA, Griffiths MR, Wong D, Pitman AG, Hicks RJ. Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data. Eur J Nucl Med Mol Imaging 2002;29:1016–23.PubMedGoogle Scholar
  7. 7.
    Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003;30:1444–9.PubMedGoogle Scholar
  8. 8.
    Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small lung cancer. J Clin Oncol 2004;22:2357–62.PubMedGoogle Scholar
  9. 9.
    Toloza EM, Harpole L, McCrory DC. Non-invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123:137–46S.PubMedGoogle Scholar
  10. 10.
    Toloza EM, Detterbeck F. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123:157–66S.PubMedGoogle Scholar
  11. 11.
    Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428–36.PubMedGoogle Scholar
  12. 12.
    Australian Institute of Welfare and Health; Cancer specific data cube. http://www.aihw.gov.au/cancer/datacubes/index.html
  13. 13.
    Kelly RF, Tran T, Holmstrom A, Murar J, Sergurola RJ. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-d-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413–23.PubMedGoogle Scholar
  14. 14.
    Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med Mol Imaging 2000;27 11:1598–609.Google Scholar
  15. 15.
    Abe K, Kosuda S, Kusano S. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma-reassessment based on the Revised Japanese National Insurance Reimbursement System. Ann Nucl Med 2003;17(8):649–55.PubMedGoogle Scholar
  16. 16.
    Gugiatti A, Grimaldi A, Rossetti C, Lucignani G, De Marchis D, Borgonovi E, et al. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. Q J Nucl Med Mol Imaging 2004;48(1):49–61.PubMedGoogle Scholar
  17. 17.
    Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada. Med Sci Monit 2004;10(5):73–80.Google Scholar
  18. 18.
    Tshushima Y, Endo K. Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules. Med Sci Monit 2004;10(5):65–72.Google Scholar
  19. 19.
    Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003;75:231–6.PubMedGoogle Scholar
  20. 20.
    Berlangieri SU, Scott AM. Metabolic staging of lung cancer. N Engl J Med 2000;343:290–2.PubMedGoogle Scholar
  21. 21.
    Scott AM. Current status of positron emission tomography in oncology. Int Med J 2001;31:27–36.Google Scholar
  22. 22.
    Lardinois D, Weder W, Hany TF, Kanel EM, Korom S, Seifer B, et al. Staging of non-small cell lung cancer with integrated positron-emission tomography and computer tomography. N Engl J Med 2003;348:2500–7.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Kelvin K. Yap
    • 1
  • Kenneth S. K. Yap
    • 1
  • Amanda J. Byrne
    • 1
  • Salvatore U. Berlangieri
    • 1
  • Aurora Poon
    • 1
  • Paul Mitchell
    • 2
  • Simon R. Knight
    • 3
  • Peter C. Clarke
    • 3
  • Anthony Harris
    • 1
  • Andrew Tauro
    • 1
  • Christopher C. Rowe
    • 1
    • 4
  • Andrew M. Scott
    • 1
    • 2
    • 4
    • 5
  1. 1.Centre for PETUniversity of Melbourne, Austin HospitalHeidelbergAustralia
  2. 2.Ludwig Institute for Cancer ResearchUniversity of Melbourne, Austin HospitalHeidelbergAustralia
  3. 3.Department of Thoracic SurgeryUniversity of Melbourne, Austin HospitalHeidelbergAustralia
  4. 4.Department of MedicineUniversity of Melbourne, Austin HospitalHeidelbergAustralia
  5. 5.Center for PETAustin HospitalHeidelbergAustralia

Personalised recommendations